Skip to Content
Merck
All Photos(1)

Documents

Y0000666

Terazosin for system suitability

CRS, European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Terazosin hydrochloride dihydrate, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H25N5O4 · HCl · 2H2O
CAS Number:
70024-40-7
Molecular Weight:
459.92
MDL number:
MFCD00941408
UNSPSC Code:
41116107
PubChem Substance ID:
329831082
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

terazosin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.O.Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

InChI key

NZMOFYDMGFQZLS-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Looking for similar products? Visit Product Comparison Guide

General description

Terazosin hydrochloride is a quinazoline derivative. It is a alpha-1-selective adrenoceptor blocking agent. It has been used to treat hypertension, as it helps the blood vessels to relax, expand and improves blood flow.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

It may be used as drug standard stock solution for determination of terazosin hydrochloride dihydrate using potentiometric and fluorimetric techniques.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000622

Terazosin impurity A, European Pharmacopoeia (EP) Reference Standard

1643463

Terazosin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1643474

Terazosin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1643485

Terazosin Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0000621

Terazosin hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0000665

Terazosin impurity E, European Pharmacopoeia (EP) Reference Standard

Y0000624

Terazosin impurity N, European Pharmacopoeia (EP) Reference Standard

1643452

Terazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1721

Terazosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002286

Terazosin for system suitability A, European Pharmacopoeia (EP) Reference Standard

PHR3137

Terazosin Related Compound A, certified reference material, pharmaceutical secondary standard

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gholamreza Mokhtari et al.
Urologia internationalis, 87(1), 19-22 (2011-05-21)
We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents. In this double-blind randomized clinical trial, 73 patients with unilateral ureteral stone and hydroureteronephrosis who underwent insertion
M R Yadav et al.
Pharmaceutical biology, 50(4), 439-442 (2011-12-06)
The problem of hypertension has gained enormous proportions in the past decade. Multifactorial etiology and complex pathophysiology of the disease has rendered the treatment of the disease a hard task. Sympathetic nervous system and the renin-angiotensin-aldosterone system are primary contributors
Man Liu et al.
Chirality, 24(12), 1047-1050 (2012-08-14)
The purpose of this study was to elucidate the pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. After a single oral dose of 2-mg terazosin, the plasma concentrations of terazosin enantiomers were measured over the course of 48 h
Laurel E Ecke et al.
Neuroreport, 23(5), 325-330 (2012-02-18)
The rewarding properties of psychomotor stimulants are traditionally thought to be independent of norepinephrine. Recent findings, however, suggest that local noradrenergic signaling through α1 receptors in the medial prefrontal cortex and the ventral tegmental area - brain regions critically important
Stephanie C Lazzaro et al.
Learning & memory (Cold Spring Harbor, N.Y.), 17(10), 489-493 (2010-09-28)
Norepinephrine receptors have been studied in emotion, memory, and attention. However, the role of alpha1-adrenergic receptors in fear conditioning, a major model of emotional learning, is poorly understood. We examined the effect of terazosin, an alpha1-adrenergic receptor antagonist, on cued
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service